Welcome to our dedicated page for SCYNEXIS news (Ticker: SCYX), a resource for investors and traders seeking the latest updates and insights on SCYNEXIS stock.
SCYNEXIS, Inc. develops therapies for severe rare diseases and difficult-to-treat fungal infections. The company’s updates center on SCY-770, a clinical-stage oral direct AMPK activator for autosomal dominant polycystic kidney disease, and SCY-247, a second-generation triterpenoid antifungal therapy in development for invasive candidiasis and prophylaxis of invasive fungal disease.
SCYNEXIS news also covers its fungerp antifungal platform, FDA designations for SCY-247, scientific presentations, financial results, and corporate actions. The company has licensed ibrexafungerp, including BREXAFEMME® for vulvovaginal candidiasis and reduction in recurrent vulvovaginal candidiasis, to GSK, making collaboration and license-agreement updates a recurring disclosure theme.
SCYNEXIS (NASDAQ: SCYX) completed a transformative asset acquisition of PXL-770 (now SCY-770), a clinical-stage oral, selective direct AMPK activator for autosomal dominant polycystic kidney disease (ADPKD). The company will pursue a Phase 2 proof-of-concept study beginning in Q4 2026, with an early efficacy readout expected in H2 2027. SCY-770 has U.S. FDA Orphan Drug Designation. Transaction terms include an $8 million upfront payment plus up to $8 million in development milestones and up to $180 million in commercial milestones.
SCYNEXIS (NASDAQ: SCYX) reported full-year 2025 results and a corporate update highlighting a $24.8M one-time payment from GSK, year-end cash, cash equivalents and investments of $56.3M and a cash runway of more than two years. The company advanced SCY-247, began IV dosing (topline data H2 2026), plans an expanded access program H1 2026, and received QIDP and Fast Track designations.
Full-year 2025 revenue totaled $20.6M versus $3.7M in 2024; R&D expense fell 15.6% to $22.3M.
SCYNEXIS (NASDAQ: SCYX) announced dosing of first participants in a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of intravenous SCY-247 for invasive candidiasis and prophylaxis against invasive fungal disease. FDA QIDP and Fast Track designations were previously granted. Results from the IV trial are expected in 2026. The company noted positive SAD/MAD oral SCY-247 data in September 2025 showing target exposures at lower doses and is exploring non-dilutive funding to support the program.
SCYNEXIS (NASDAQ: SCYX) announced presentations on its second‑generation fungerp, SCY-247, at the inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI), Jan 28–30, 2026, in Las Vegas.
The company said SCY-247 showed potent in vitro and in vivo antifungal activity, a favorable safety profile, and supportive pharmacokinetics in clinical investigations to date. Oral presentation: Jan 29, 9:00–10:30am; poster: Jan 30. Materials will be posted in the company’s Publications and Presentations section after the meeting.
SCYNEXIS (NASDAQ: SCYX) announced that the U.S. FDA granted QIDP and Fast Track designations for its second‑generation triterpenoid antifungal, SCY-247. The company noted QIDP will provide at least 10 years of post‑approval market exclusivity and Fast Track may enable more frequent FDA interaction, rolling review, and eligibility for accelerated approval or priority review. SCYNEXIS plans to initiate a Phase 1 IV study and a Phase 2 oral study in invasive candidiasis in 2026, and aims to release oral proof‑of‑concept data the same year. SCY-247 has shown preclinical activity against multi‑drug resistant fungi including Candida auris and azole‑resistant Aspergillus.
SCYNEXIS (NASDAQ: SCYX) received a 180-calendar-day extension from Nasdaq to regain compliance with the minimum bid price rule, extending the cure period to June 15, 2026.
Nasdaq confirmed SCYNEXIS meets other continued listing criteria and the company said it may use a reverse stock split if needed. Management also confirmed plans to complete a Phase 1 IV study and seek proof-of-concept Phase 2 oral data for investigational antifungal SCY-247 in invasive candidiasis, while maintaining commitments to regain full Nasdaq compliance.
SCYNEXIS (NASDAQ: SCYX) completed transfer of the BREXAFEMME (ibrexafungerp) NDA to GSK on November 19, 2025. GSK can now initiate regulatory interactions with the FDA to discuss a U.S. relaunch for vulvovaginal candidiasis (VVC) and refractory VVC (rVVC). Following a relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones plus royalties, which are payable net of amounts due to Merck and expected in the low- to mid-single digit percentage range. The company describes these payments as a potential source of future non-dilutive capital.
SCYNEXIS (NASDAQ: SCYX) announced it is a collaborator in a new Center of Excellence in Translational Research jointly led by Hackensack Meridian CDI and Johns Hopkins Bloomberg School of Public Health that received a federal five-year grant from NIAID.
The CETR expects to receive about $7 million annually, contingent on availability of funds, to support five projects including a novel series of SCYNEXIS’ proprietary triterpenoid antifungals (next‑generation fungerps) aimed to advance selected preclinical candidates toward IND readiness for resistant fungal infections.
SCYNEXIS (NASDAQ: SCYX) reported Q3 2025 results and a corporate update on Nov 5, 2025. The company will receive a one-time payment of $24.8 million from GSK related to termination of the Phase 3 MARIO study and expects a post-payment cash runway of greater than two years.
SCYNEXIS reported $37.9 million in cash, cash equivalents and investments as of Sept 30, 2025, net loss of $8.6 million (Q3 2025) and plans to start an IV Phase 1 for SCY-247 in Q1 2026 and a Phase 2 oral study with proof-of-concept data expected in 2026. GSK is pursuing a BREXAFEMME relaunch and SCYNEXIS may receive up to $146 million in annual net sales milestones plus low-to-mid single-digit royalties.
SCYNEXIS (NASDAQ:SCYX) resolved its disagreement with GSK over restarting the Phase 3 MARIO study on invasive candidiasis and will wind down and terminate MARIO.
As part of the resolution, SCYNEXIS will receive a $22.0 million payment plus an additional $2.3 million for wind-down activities. The company said the payment, combined with cash on hand and the removal of future MARIO expenses, extends its cash runway to more than two years. GSK reiterated its commitment to commercialize BREXAFEMME and to collaborate on transferring the BREXAFEMME NDA to GSK by end of 2025, with GSK planning FDA interactions in 2026 regarding relaunch in the U.S.